Urology

Episodes 1-15 of 27

• 

  RestartResume

  Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

  CME/CE

  Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer

  • 

    

    Neal Shore, MD, FACS

    Peer

  • 

    

    Sarah Psutka, MD, MS

    Peer

  0.25 credits

• 

  RestartResume

  Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs

  CME/CE

  Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs

  • 

    

    Pedro Barata, MD, MSc, FACP

    Peer

  • 

    

    Sumanta K. Pal, MD, FASCO

    Peer

  1.00 credits

• 

  RestartResume

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  CME/CE

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

    Peer

  • 

    

    Shilpa Gupta, MD

    Peer

  0.50 credits

• 

  MinuteCE®

  Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

    Peer

  • 

    

    Lillibeth Velasco, MSN, RN

    Peer

  0.50 credits 3 episodes

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 credits 10 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits
• advertisement

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits
• advertisement

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 1
• 2
• Next